Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications [0.03%]
全球及中国原发性肝癌流行趋势分析及对疾病管理的启示——基于GLOBOCAN 2022数据
Jiayan Yan,Jiayi Wang,Jian Fan et al.
Jiayan Yan et al.
Primary liver cancer remains a significant global public health challenge, characterized by persistently high incidence and mortality. This review synthesizes current epidemiological data to analyze trends and etiological shifts, with parti...
Resmetirom and thyroid hormone receptor-targeted treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) [0.03%]
Resmetirom以及甲状腺激素受体靶向治疗代谢功能障碍相关脂肪性肝病(MASLD)
Chang-Hai Liu,Qing-Min Zeng,Teng-Yue Hu et al.
Chang-Hai Liu et al.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a rapidly increasing chronic disease worldwide, particularly among patients with type 2 diabetes. Its severe form, metabolic dysfunction-associated steatohepatitis (MASH), ...
Comparison of patients with hepatitis B virus-associated hepatocellular carcinoma: Data from two hospitals from Turkey and China [0.03%]
乙肝病毒相关性肝细胞癌患者的临床特征对比分析：来自中国和土耳其两家医院的数据
Brian I Carr,Fajuan Rui,Volkan Ince et al.
Brian I Carr et al.
Aims: There are many studies on the incidence of hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC), but very little is known about the HCC features in different populations. The study aimed to compare char...
The natural history of patients with compensated cirrhosis and elevated hepatic venous pressure gradient [0.03%]
肝静脉压力梯度升高而处于代偿期的肝硬化患者的自然病史研究
Andrew Wortham,Ali Khalifa,Don C Rockey
Andrew Wortham
Aims: Portal hypertension is a major complication of liver cirrhosis. Hepatic venous pressure gradient (HVPG) appears to be one of the best surrogates of clinical outcomes. However, the utility of elevated HVPG in predict...